Cargando…

DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3

BACKGROUND: Studies report conflicting evidence regarding the existence of a DCIS-associated premalignant pathway in BRCA mutation carriers. We aimed to examine the prevalence, phenotype, and expression of oncodrivers in pure DCIS (pDCIS) and invasive breast cancer with concurrent DCIS (IBC + DCIS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Rachel L., Mick, Rosemarie, Lee, Kathreen, Graves, Holly L., Nathanson, Katherine L., Domchek, Susan M., Kelz, Rachel R., Zhang, Paul J., Czerniecki, Brian J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619378/ https://www.ncbi.nlm.nih.gov/pubmed/26496879 http://dx.doi.org/10.1186/s12967-015-0698-3

Ejemplares similares

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among BRCA1/BRCA2 Mutation Carriers
por: Faermann, Renata, et al.
Publicado: (2022)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells
por: Namjoshi, Prachi, et al.
Publicado: (2019)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
por: Rebbeck, Timothy R., et al.
Publicado: (2009)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Prostate screening uptake in Australian BRCA1 and BRCA2 carriers
por: McKinley, Joanne M, et al.
Publicado: (2007)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
por: Osorio, A, et al.
Publicado: (2011)

Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
por: Mitchell, Rachel, et al.
Publicado: (2018)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
por: Bougie, O., et al.
Publicado: (2011)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
por: Neuhausen, Susan L, et al.
Publicado: (2009)

Cancer risks among BRCA1 and BRCA2 mutation carriers
por: Levy-Lahad, E, et al.
Publicado: (2007)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
por: Buckley, Kole H., et al.
Publicado: (2022)

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
por: Silvestri, Valentina, et al.
Publicado: (2016)

Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
por: Boursi, Ben, et al.
Publicado: (2023)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
por: Osorio, A, et al.
Publicado: (2009)

Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction
por: Tai, Yu Chuan, et al.
Publicado: (2008)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
por: Hakkaart, Christopher, et al.
Publicado: (2022)

Exploring the acceptability of, and preferences for, an ongoing support network for known BRCA1 and BRCA2 mutation carriers
por: Hughes, L, et al.
Publicado: (2008)

Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
por: Maia, Ana-Teresa, et al.
Publicado: (2012)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
por: Whittemore, A S, et al.
Publicado: (2004)

Management of the asymptomatic BRCA mutation carrier
por: Teller, Paige, et al.
Publicado: (2010)

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits
por: Schrijver, Lieske H, et al.
Publicado: (2022)

Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence
por: Conduit, Ciara, et al.
Publicado: (2021)

Oncodriver inhibition and CD4(+) Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies
por: Rosemblit, Cinthia, et al.
Publicado: (2018)

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
por: Kuchenbaecker, Karoline B., et al.
Publicado: (2017)

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
por: Olivier, R I, et al.
Publicado: (2004)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
por: Antoniou, Antonis C, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_q7o9qb4t2i4uni93ujgjll2q7o